Hostname: page-component-cc8bf7c57-j4qg9 Total loading time: 0 Render date: 2024-12-11T23:01:19.591Z Has data issue: false hasContentIssue false
  • English
  • Français

The tyramine conjugation test and depression

Published online by Cambridge University Press:  18 September 2015

J.G. Storosum ,
F. de Jonghe ,
H.F.A. Schalken ,
J. Huyser  and
H.N. Sno
Get access Rights & Permissions [Opens in a new window]

Summary

In this article the value of the tyramine conjugation test (TCT) as a predictor of the response to antidepressive medication is reviewed. The TCT seems of little discomfort for the patient, is easy to perform and is suggested to have a high sensitivity and specificity. In addition, there are indications that a decreased tyamine conjugation could be a traitmarker for the vulnerability of depression. Hypotheses concerning the, as yet unclear etiology of the decreased tyramine are reviewed.

Keywords

tyramineconjugation testdepressionantidepressivestyramineconjugatie testdepressieantidepressiva
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 2 , Issue 3 , September 1990 , pp. 72 - 76
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Balan, R. Biological indicators of antidepressant treatment outcome. Clin Neuropharmacol 1989; 12:195–214.CrossRefGoogle Scholar
2.Caroll, BJ. The dexamethason suppressie test for melancholia. Br J Psychiatry 1982; 140: 292–304.CrossRefGoogle Scholar
4.Joyce, PR, Paykel, ES. Predictors of drug respons in depression. Arch gen Psychiat 1989; 46:89–99.CrossRefGoogle Scholar
5.Hale, AS, Sandler, M, Hannah, P, Bridges, PK. Tyramine conjugation test for prediction of treatment response in depressed patients. Lancet 1989; 4:234–6.CrossRefGoogle Scholar
6.Hale, AS, Walker, PL, Bridges, PK, Sandler, M. Tyramine-conjugation defecit as a trait-marker in endogenous depressive illness. J psychiat Res 1986; 20:251–260.CrossRefGoogle Scholar
7.Da Prada, M, Zurchner, G, Wuthrich, I, Haefely, WE. On tyramine, food, beverages and the MAO inhibitor moclobemide. J Neural Transm 1988; 26(suppl): 31–56.Google ScholarPubMed
8.Usdin, E, Sandler, M, eds. Trace amines and the brain. MDekker Inc., New York: 1976.Google Scholar
9.Boulton, AA. The Tyramines: Funktionally significant biogenic amines or metabolic accidents? Life Sci 1978; 23:659–72.CrossRefGoogle ScholarPubMed
10.Burn, JH, Rand, MJ. The action of sympathicomimetic amines in animals treated with reserpine. J Physiol (Lond) 1958; 144:314–36.CrossRefGoogle Scholar
11.Eruier, US, Lishajko, F. Release of noradrenaline from adrenergic transmitter granles by tyramine. Experentia 1960; 16:376–7.Google Scholar
12.Haefely, W, Hürlimann, A, Thoenen, H. The responses of tyramine of the normal and denervated nictitating membrane of the cat: analysis of the mechanisms and sites of action. Br J Pharmac 1963; 21:27–38.Google ScholarPubMed
13.Boulton, AA, Jurio, AV. Cerebral decarboxylation of meta- and para-tyrosine. Experentia 1983; 39: 130–4.CrossRefGoogle ScholarPubMed
14.Boulton, AA, Dyck, LE. Biosynthesis and excretion of meta- and para-tyramine in the rat. Life Sci 1974; 23:659–72.CrossRefGoogle Scholar
15.Silkaitis, RP, Mosnaim, AD. Pathways linking L-phenylalanine and 2-phenylethyl-amine with p-tyramine in rabbit brain. Brain Res 1976; 114: 105–15.CrossRefGoogle Scholar
16.Karoun, F. The origin of central and peripheral p-hydroxy-phenylacetic acid in man and rat. In: Boulton, AA, Maitre, L, Bieck, PR, Riederer, P, eds. Neuropharmacology of the Trace Amines. Clifton NJ: Humana press, 1985b: 433–50.CrossRefGoogle Scholar
17.Youdim, MBH, Bakhle, YS, Ben-Hurai, RR. Comparison of monoamine oxidase activity in perfused organs in vitro. In: Singer, TP, Von Korff, RW, Murphy, DL, eds Monoamine oxidase: Structure, Function and Altered Functions. New York: Acad Press, 1979; 361–77.Google Scholar
18.Youdim, MBH, Bakhle, YS, Ben-Harari, RR. Inactivation of monoamines by the lung. Ciba Foundation Symposium 78. Amsterdam: Elsevier 1980: 105–28.Google Scholar
19.Udea, T, Kinemuchi, H. Deamination of some biogenic monoamines in rat lung by monoamine oxidase and benzylamine. Biogenic Amines 1984; 1: 179–92.Google Scholar
20.Tacker, M, Mclsaak, WM, Creaven, P. Metabolism of tyramine 1-3C by the rat. Biochem Pharmacol 1970; 19:2763–73.CrossRefGoogle Scholar
21.Karoun, F. On the origin of central and peripheral p-hydroxypheny-lacetic acid in rats: a comparison with metabolites of biogenic amines and other than p-tyramine. Biogenic Amines 1985; 4:269–82.Google Scholar
22.Tipton, KF, Houslay, MD, Mantle, TJ. The nature and locations of the multiple forms of monoamine oxidase. In: Monoamine oxidase and its inhibition. Ciba Foundation Symposium 39. Amsterdam: Elsevier, 1976:5–31.Google Scholar
23.Hasan, F, McCrodden, JM, Kennedy, NP, Tipton, KF. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. In Youdim, MBH, Da Prade, M, Amrein, R, eds. The cheese effect and new reversible MAO-A inhibitors. J neural Transm (Suppl) 1988; 26: 1–9.Google ScholarPubMed
24.Marley, E, Blackwell, B. Interactions of monoamineoxidase inhibitors, amines and foodstuffs. Adv Pharmacol Chemotherap 1970; 8: 185–239.CrossRefGoogle Scholar
25.Youdim, MBH, Bonham Carter, S, Sandler, M, Hanington, E, Wilkinson, M. Conjugation defect in tyramine-sensitive migraine. Nature 1971; 230: 127.CrossRefGoogle ScholarPubMed
26.Sandler, M, Bonham Carter, S, Cuthbert, MF, Pare, CMB. Is there an increase in monoamine-oxidase activity in depressive illness? Lancet 1975; 1: 1045–1949.CrossRefGoogle ScholarPubMed
27.Harrison, WM, Cooper, TB, Stewart, JW, Quitkin, FM, McGrath, PJ, Liebowitz, MR, Rabkin, JR, Markowitz, MPH, Klein, DF. The tyramine challenge test as a marker for melancholia. Arch gen Psychiat 1984;41:681–85.CrossRefGoogle ScholarPubMed
28.Klein, DF. Endogenomorphic depression: A conceptual and terminological division. Arch gen Psychiat 1974; 31:447–54.CrossRefGoogle Scholar
29.Sandler, M, Ruthven, CRJ, Goodwin, BL, Reynolds, GP, Rao, VAR, Coppen, A. Deficient production of tyramine and octopamine in cases of depression. Nature 1979; 278:357–8.CrossRefGoogle ScholarPubMed
30.Bonham Carter, SM, Sandler, M, Goodwin, BL, Sepping, P, Bridges, PK. Decreased urinary output of tyramine and its metabolites in depression. Br J Psychiat 1978; 132: 125–32.CrossRefGoogle Scholar
31.Bonham Carter, S, Sandler, M, Sepping, P, Bridges, PK. Decreased conjugated tyramine output in depression: Gastrointestinal factors. Br J Clin Pharmacol 1978; 5:269–72.CrossRefGoogle Scholar
32.Bonham Carter, SM, Goodwin, BL, Sandler, M. Decreased conjugated tyramine output in depression: The effect of oral L-cysteine. Br J Clin Pharmac 1980; 10:305–8.CrossRefGoogle Scholar
33.Stewart, JW, Harrison, W, Cooper, TB, Quitken, FM. Tyramine sulfate excretion may be a better predictor of antidepressant response than monoamine oxidase activity. Psychiat Res 1988; 25: 195–201.CrossRefGoogle ScholarPubMed
34.Anderson, RJ, Weinshilboum, RM. Phenolsulphotransferase in human tissue: radiochemical enzymatic assay and biochemical properties. Clin Chim Acta 1980; 103:79–90.CrossRefGoogle ScholarPubMed
35.Hart, RF, Renskers, KJ, Nelson, EB, Roth, JA. Localization and characterization of phenol sulfotransferase in human platelets. Life Sci 1979; 24: 125–39.CrossRefGoogle ScholarPubMed
36.Rein, G, Glover, V, Sandler, M. Sulphate conjugation of biologically active monoamines and their metabolites by human platelet phenolsulphotransferase. Clin Chim Acta 1981; 111: 247–56.CrossRefGoogle ScholarPubMed
37.Bonham Carter, SM, Glover, V, Sandler, M, Gillman, PK, Bridges, PK. Human platelet phenolsulphotransferase: separate control of two forms and activity range in depressive illness. Clin Chim Acta 1981; 117:333–44.CrossRefGoogle Scholar
38.Sandler, M, Bonham Carter, SM, Walker, PL. Tyramine conjugation deficit as a trait-marker in depression. Psychopharmacol Bull 1983; 19:501–2.Google Scholar
39.Bonham Carter, SM, Reveley, MA, Sandler, M, Dewhurst, J, Little, BC, Hayworth, J, Priest, RG. Decreased urinary output of conjugated tyramine is associated with lifetime vulnerability to depressive illness. Psychiat Res 1980; 3: 13–21.CrossRefGoogle Scholar